Have Relmada Therapeutics insiders bought shares recently?

No open-market purchase by an insider of Relmada Therapeutics was filed in the last 90 days. The latest on record was on Aug 28, 2025.

How often do Relmada Therapeutics insiders buy and sell shares?

Since 2015, Relmada Therapeutics insiders reported 81 open-market purchases and 81 sales on Forms 4 and 5, with purchases in 7 different years, most recently 2025.

Who is selling Relmada Therapeutics stock?

No open-market sale by an insider of Relmada Therapeutics (RLMD) was filed with the SEC in the last 90 days.

Do members of Congress trade RLMD?

No trade in Relmada Therapeutics (RLMD) was disclosed by a member of Congress in the last 12 months.

Where does this data come from?

From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.

Relmada Therapeutics (RLMD) insider trading and stock trades

OQRO

Ask OQRO about this page

Ask

Want the short version?

Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.

Explain this page What did insiders at RLMD buy and sell in the last 90 days?Which members of Congress and which funds traded RLMD recently?

Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.

RLMD price and disclosed activity

+8.5% (+$0.33) from Nov 13, 2025 to Nov 13, 2026 · adjusted daily closes

13F holdings, by quarter end

Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Fund 13F reports are quarter-end snapshots filed up to 45 days later, so they are shown under the chart across the quarter they describe, not on the price line. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.

Insider open-market trades, filed in the last 90 daysNoneNo open-market trades reportedInsider trades →Congress trades, disclosed in the last 90 daysNoneNo House or Senate report names this stockCongress →Fund 13F changes, quarter ending Jun 30, 20260 added · 1 cut1 followed fund; holdings as of the quarter end, filed by Aug 14, 2026Fund moves →Federal contracts starting in the last 12 monthsNoneNo award found for this companyContracts →

Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.

Pharmaceutical Preparations company based in Coral Gables, Fl.

Last 12 months

+8.5%

S&P 500 +12.3% over the same dates

Market value

$449M

Close of Nov 13, 2026 × shares outstanding (per ADS where it applies)

S&P 500 +12.3% over the same dates. Prices adjusted for splits and dividends.

Short interest: 10.8M shares sold short (10.2% of shares outstanding), −11.0% vs the previous count, 6.4 days of normal trading to buy them back. FINRA, as of Oct 30, 2026.

On the public record for Relmada Therapeutics over the 12 months to Nov 14, 2026: 2 clinical trials.

Latest results: quarter ending Jun 30, 2026

Revenue

—

Free cash flow, last 12 months

—

Cash from operations minus capital spending

Net debt

—

Debt —, cash $11.3M, at Jun 30, 2026

Net income, last 12 months

−$61.9M

From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Nov 12, 2026.

Insider buying and selling since 2015

Insiders of Relmada Therapeutics reported 81 open-market purchases and 81 sales since 2015; purchases in 7 different years, most recently 2025.

Year	Bought	Sold
2025	$639K11×11 trades	—
2024	$1.31M17×17 trades	—
2023	$32K1×1 trade	—
2022	$116K1×1 trade	$956K7×7 trades
2021	—	$11.1M68×68 trades
2020	—	$655K6×6 trades
2019	$268K9×9 trades	—
2018	$141K2×2 trades	—
2015	$180K40×40 trades	—

Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.

When insiders usually buy

Last results

Nov 12, 2026

Within the 30 days after it, until Dec 12, 2026

Next results, expected

Not announced

Purchases after results

17%

5 of 30 insider purchases since 2021 came within 30 days after a results announcement

From Relmada Therapeutics's own results filings (8-K Item 2.02) and its insiders' Forms 4 and 5. Many companies only let insiders trade in a period after results; OQRO does not know Relmada Therapeutics's policy and only shows the pattern in the filings. A purchase made long after results, at a company whose insiders usually buy right after them, is marked “Bought outside the usual window”.

Late-stage clinical trials

1 active phase 3 trial and 1 active phase 2 trial led by this company, mostly in non muscle invasive bladder cancer, bladder (urothelial, transitional cell) cancer. The ones with the nearest registered primary completion date still ahead:

Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.

Latest

See everything

Fund moves

3.63MShares reported · -1.08M vs prior quarter

Filed 3mo ago

3 tracked managers disclosed the same change for Q2 2026. From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.

More Official record

Fund moves

Want the short version?

Relmada Therapeutics

How this filing works

Questions about Relmada Therapeutics insider trading

Insiders who traded Relmada Therapeutics

Other Pharmaceutical Preparations companies

RLMD price and disclosed activity

Latest results: quarter ending Jun 30, 2026

Insider buying and selling since 2015

When insiders usually buy

Late-stage clinical trials

Latest

3.63MShares reported · -1.08M vs prior quarter

4.72MShares reported · +2.11M vs prior quarter

2.61MShares reported

~$137Kacross 2 transactionsin 1 filing

Late-stage clinical trials

When insiders usually buy

Insider buying and selling since 2015